Anti-inflammatory therapies were associated with reduced risk of myocardial infarction in patients with established cardiovascular disease or high cardiovascular risks: A systematic review and meta-analysis of randomized controlled trials

被引:19
作者
Li, Zonglin [1 ]
Lin, Chu [1 ]
Cai, Xiaoling [1 ,2 ]
Hu, Suiyuan [1 ]
Lv, Fang [1 ]
Yang, Wenjia [1 ]
Zhu, Xingyun [1 ]
Ji, Linong [1 ,2 ]
机构
[1] Peking Univ Peoples Hosp, Dept Endocrinol & Metab, Beijing, Peoples R China
[2] Peking Univ Peoples Hosp, Dept Endocrinol & Metab, 11 Xizhimen South St, Beijing 100044, Peoples R China
基金
中国国家自然科学基金; 北京市自然科学基金;
关键词
Anti-inflammatory; Inflammation; Myocardial infarction; Cardiovascular disease; ACUTE CORONARY SYNDROME; NLRP3; INFLAMMASOME; GLOBAL BURDEN; P-SELECTIN; PART; ATHEROSCLEROSIS; HEART; INTERLEUKIN-1; IL-1; RECEPTOR;
D O I
10.1016/j.atherosclerosis.2023.06.972
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: We aimed to evaluate the association between anti-inflammatory therapies and the inci-dence of cardiovascular events in patients with established cardiovascular disease (CVD) or high cardiovascular risks.Methods: Literature retrieval was conducted in PubMed, Medline, Embase, the Cochrane Central Register of Controlled Trials and Clinicaltrial.gov website from the inception to December 2022. Randomized controlled trials comparing anti-inflammatory therapies with placebo in patients with established CVD or high cardiovas-cular risks were included. The results of the meta-analysis were computed as the risk ratio (RR) with 95% confidence interval (CI).Results: Compared with placebo, anti-inflammatory therapies were associated with decreased incidence of myocardial infarction (MI) (RR = 0.93, 95% CI, 0.88 to 0.98), which was mainly driven by therapies targeting central IL-6 signaling pathway (RR = 0.83, 95% CI, 0.74 to 0.93). IL-1 inhibitors treatment was associated with reduced risks of heart failure (RR = 0.38, 95% CI, 0.18 to 0.80) while lower incidence of stroke was observed in patients with colchicine treatment (RR = 0.47, 95% CI, 0.28 to 0.77). MI events were less frequent in patients over 65 years of age (RR = 0.90, 95% CI, 0.83 to 0.98) or with follow-up duration over 1 year (RR = 0.90, 95% CI, 0.85 to 0.96) when comparing anti-inflammatory therapies with placebo.Conclusions: Anti-inflammatory therapies, especially those targeting the central IL-6 signaling pathway, may serve as promising treating strategies to ameliorate the risk of MI. IL-1 inhibitor and colchicine were associated with decreased risks of heart failure and stroke, respectively. MI risk reduction by anti-inflammatory therapies seemed to be more prominent in older patients with long follow-up duration.
引用
收藏
页数:11
相关论文
共 86 条
[1]   Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction [J].
Abbate, Antonio ;
Salloum, Fadi N. ;
Vecile, Elena ;
Das, Anindita ;
Hoke, Nicholas N. ;
Straino, Stefania ;
Biondi-Zoccai, Giuseppe G. L. ;
Houser, Jon-Erik ;
Qureshi, Ian Z. ;
Ownby, Evan D. ;
Gustini, Edoardo ;
Biasucci, Luigi M. ;
Severino, Anna ;
Capogrossi, Maurizio C. ;
Vetrovec, George W. ;
Crea, Filippo ;
Baldi, Alfonso ;
Kukreja, Rakesh C. ;
Dobrina, Aldo .
CIRCULATION, 2008, 117 (20) :2670-2683
[2]   Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease [J].
Abbate, Antonio ;
Toldo, Stefano ;
Marchetti, Carlo ;
Kron, Jordana ;
Van Tassell, Benjamin W. ;
Dinarello, Charles A. .
CIRCULATION RESEARCH, 2020, 126 (09) :1260-1280
[3]   Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction [J].
Abbate, Antonio ;
Trankle, Cory R. ;
Buckley, Leo F. ;
Lipinski, Michael J. ;
Appleton, Darryn ;
Kadariya, Dinesh ;
Canada, Justin M. ;
Carbone, Salvatore ;
Roberts, Charlotte S. ;
Abouzaki, Nayef ;
Melchior, Ryan ;
Christopher, Sanah ;
Turlington, Jeremy ;
Mueller, George ;
Garnett, James ;
Thomas, Christopher ;
Markley, Roshanak ;
Wohlford, George F. ;
Puckett, Laura ;
de Chazal, Horacio Medina ;
Chiabrando, Juan G. ;
Bressi, Edoardo ;
Del Buono, Marco Giuseppe ;
Schatz, Aaron ;
Vo, Chau ;
Dixon, Dave L. ;
Biondi-Zoccai, Giuseppe G. ;
Kontos, Michael C. ;
Van Tassell, Benjamin W. .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (05)
[4]   Reappraising the role of inflammation in heart failure [J].
Adamo, Luigi ;
Rocha-Resende, Cibele ;
Prabhu, Sumanth D. ;
Mann, Douglas L. .
NATURE REVIEWS CARDIOLOGY, 2020, 17 (05) :269-285
[5]   Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice [J].
Alexander, Matthew R. ;
Moehle, Christopher W. ;
Johnson, Jason L. ;
Yang, Zhengyu ;
Lee, Jae K. ;
Jackson, Christopher L. ;
Owens, Gary K. .
JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (01) :70-79
[6]   Interleukin-6 promotes a sustained loss of endothelial barrier function via Janus kinase-mediated STAT3 phosphorylation and de novo protein synthesis [J].
Alsaffar, Hiba ;
Martino, Nina ;
Garrett, Joshua P. ;
Adam, Alejandro P. .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2018, 314 (05) :C589-C602
[7]   The pathophysiology of cigarette C-V smoking and cardiovascular disease - An update [J].
Ambrose, JA ;
Barua, RS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (10) :1731-1737
[8]   Infarct in the Heart: What's MMP-9 Got to Do with It? [J].
Becirovic-Agic, Mediha ;
Chalise, Upendra ;
Daseke, Michael J., II ;
Konfrst, Shelby ;
Salomon, Jeffrey D. ;
Mishra, Paras K. ;
Lindsey, Merry L. .
BIOMOLECULES, 2021, 11 (04)
[9]   INTERLEUKIN-1 (IL-1) INDUCES BIOSYNTHESIS AND CELL-SURFACE EXPRESSION OF PROCOAGULANT ACTIVITY IN HUMAN VASCULAR ENDOTHELIAL-CELLS [J].
BEVILACQUA, MP ;
POBER, JS ;
MAJEAU, GR ;
COTRAN, RS ;
GIMBRONE, MA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1984, 160 (02) :618-623
[10]   Environmental Determinants of Cardiovascular Disease [J].
Bhatnagar, Aruni .
CIRCULATION RESEARCH, 2017, 121 (02) :162-180